Earnings
Since 2016 the state has offered more than $70 million in tax credits to 114 different entities and has generated about $140 million in investments into the state’s life sciences ecosystem.
Stoughton, Mass.-based Collegium Pharmaceutical is expanding its pain-treating portfolio with a $604 million buyout of Raleigh’s BioDelivery Sciences International (BDSI).
The fund will be used to target partnerships with promising early-stage biotechnology to enhance Fujifilm’s life sciences portfolio.
The London-based Financial Times reported that 83% of companies listed on stock exchanges over the past two years are now trading well below their initial public offering price.
Shares of Alnylam Pharmaceuticals are sliding in morning trading despite the news that the company’s revenues grew by 83% in 2021 compared to the previous year.
Bayer joined in the $50 million Series A for San Francisco’s Indapta Therapeutics.
As AstraZeneca released its 2021 annual financial report, a BBC documentary suggested that the way scientists and politicians politicized its COVID-19 vaccine may have cost lives.
Teva Pharmaceuticals reported solid earnings for the full year of 2021, posting $15.9 billion in revenues alongside gains of $4.1 billion from the fourth quarter alone.
As GSK moves into the new year, Chief Executive Officer Emma Walmsley predicted 2022 will be a “landmark year” for the company.
The vaccine delivered more than $12 billion in revenue to Pfizer and the company expects those earnings to vastly increase this year to $32 billion.
PRESS RELEASES